Europe Recombinant Protein Manufacturing Services Market to be Dominated by Commercial Production Services Through 2028
Rising Prevalence of Chronic Diseases
and Increasing Patient Demand for Biopharmaceuticals are driving Europe
Recombinant Protein Manufacturing Services Market in the forecast period 2024-2028.
According
to TechSci Research report, “Recombinant
Protein Manufacturing Services Market - Europe Industry Size, Share, Trends,
Opportunity, and Forecast, 2018-2028”, Europe Recombinant Protein Manufacturing Services Market stood at
USD1.11 billion and is expected to grow at a CAGR of 10.40% through 2028. The
biopharmaceutical sector is witnessing remarkable growth as researchers and
pharmaceutical companies focus on developing novel therapeutic agents,
including monoclonal antibodies, cytokines, enzymes, and vaccines. Recombinant
proteins play a pivotal role in this endeavor by serving as key components in
the production of these biologic drugs. As the demand for targeted therapies
and precision medicine escalates, the Europe Recombinant Protein Manufacturing
Services market gains traction due to its ability to provide customizable and scalable
protein production solutions. Research
in various life science fields, such as cell biology, molecular biology, and
genomics, relies heavily on recombinant proteins. These proteins serve as
essential tools for studying gene function, protein interactions, and disease
mechanisms. As academia and research institutions across Europe continue to
explore intricate biological processes, the need for a consistent supply of
high-quality recombinant proteins drives the demand for specialized
manufacturing services. Personalized
medicine is transforming healthcare by tailoring treatments to individual
patients based on their genetic makeup and specific disease characteristics.
Recombinant proteins play a crucial role in this paradigm shift, as they are
essential for developing targeted therapies that can selectively interact with
disease-associated molecules.
The Europe Recombinant Protein Manufacturing
Services market aligns with the requirements of personalized medicine, offering
the capability to produce patient-specific proteins and antibodies for
diagnostics and treatment. As
sustainability becomes a focal point in various industries, including
biotechnology, there is a growing emphasis on adopting environmentally friendly
practices throughout the production process. Recombinant protein manufacturing
services that prioritize sustainable sourcing of raw materials, efficient
production methods, and reduced waste generation are likely to gain favor among
environmentally conscious clients, further driving market growth.
However, the production of recombinant proteins
involves intricate and resource-intensive processes. From cell line development
and fermentation to downstream purification and quality control, each step can
be costly. Additionally, the need for specialized equipment, highly skilled
personnel, and advanced technologies further contributes to the overall cost of
manufacturing. Balancing quality and cost-effectiveness is a continuous
challenge for manufacturers in this sector, which may hamper the growth of the
market in the projected period.
Browse
over XX market data Figures spread through XX
Pages and an in-depth TOC on " Europe Recombinant Protein Manufacturing Services Market.”
Europe
Recombinant Protein Manufacturing Services is segmented based on Service Type, Host Cell and
End Use.
Based
on Service Type, the market is divided into Pre-clinical & Clinical
Services and Commercial Production Services. The Commercial Production Services
segment is expected to witness a rise over the forecast period. This is
attributed to the fact that commercial production service providers have
invested heavily in state-of-the-art facilities and equipment, as well as a
highly skilled workforce. This enables them to offer comprehensive services,
from gene synthesis to final product purification, ensuring consistent quality
and reliable supply.
Based
on Host Cell, the market is divided into Mammalian Cells, Bacterial Cells,
Insect Cells, Yeast & Fungi and Others. The Mammalian Cells segment is
expected to witness a rise over the forecast period. This is attributed to the
fact that mammalian cells have proven to be a versatile and effective platform
for producing complex therapeutic proteins. Their ability to perform intricate
post-translational modifications, such as glycosylation and phosphorylation,
closely mimics the native environment, yielding proteins with enhanced
bioactivity and stability.
Based
on End Use, the market is divided into Pharmaceutical & Biotechnology
Companies, Academic & Research Institutes. The Pharmaceutical &
Biotechnology Companies segment is expected to witness a rise over the forecast
period. This is attributed to the fact that various pharmaceutical &
biotechnology businesses are driving innovation in terms of service and manufacturing
capabilities and are providing commercial potential for market expansion.
Major
companies operating in Europe Recombinant Protein Manufacturing Services market
are:
- Lonza
- Boehringer Ingelheim International GmbH
- FUJIFILM Diosynth Biotechnologies
- Merck KGaA
- Bruker (InVivo BioTech Services GmbH)
- Sino Biological, Inc.
- GenScript
- Kaneka corporation (Kaneka Eurogentec S.A)
- Polyplus Transfection (Xpress Biologics)
- Boster Biological Technology
- Trenzyme GmbH
Download Free Sample Report
Customers can also request
for 10% free customization on this report.
"
Germany dominated the Europe Recombinant Protein Manufacturing Services Market
in 2022 on account of its commitment to advancing healthcare through
technological innovation, research, and proactive public health initiatives. The
country boasts a dense network of research institutions, universities, and
biotech companies, which fosters collaboration and knowledge exchange. This
ecosystem provides a fertile ground for innovation and enables the seamless
translation of scientific discoveries into commercial applications and are
creating favorable conditions to boost the Europe demand for Recombinant
Protein Manufacturing Services till 2028.” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based Europe management consulting
firm.
“Europe Recombinant Protein Manufacturing
Services Market, By Service Type
(Pre-clinical & Clinical Services and Commercial Production Services), By Host
Cell (Mammalian Cells, Bacterial Cells, Insect Cells, Yeast & Fungi and
Others), By End Use (Pharmaceutical & Biotechnology Companies, Academic
& Research Institutes),
By Region, Competition Forecast & Opportunities, 2028,
has evaluated the future growth potential of Europe Recombinant Protein
Manufacturing Services and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Europe Recombinant Protein Manufacturing
Services market.”
Contact
Mr. Ken
Mathews
708 Third
Avenue,
Manhattan,
NY,
New York
10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com